Gantz: “we can all be proud of the existence of such an institution, the existence of such scientists and the important scientific work that you are achieving”.
During the visit, IIBR leading scientists gave an update about the scientific developments and the following steps on the way to develop a vaccine and a treatment for the Corona virus.
A joint ongoing study led by IIBR researchers and physicians from Laniado and Assuta ashdod hospitals tested the viability of corona virus in patient‘s environment surfaces. The study reveal low probability of being infected due to surface contact.
IIBR will continue to characterize these antibodies and others and a biological manufacture would be sought to mass produce it for clinical use.
IIBR, using its Biology division's well-established platform for antibody engineering, have managed to isolate monoclonal antibody against the virus from blood samples that were obtain from severe COVID19 patients. It was also demonstrated that this antibody was able to effectively neutralize the virus.
IIBR, using its Biology division's well-established platform for antibody engineering, have managed to isolate monoclonal antibody against the virus, from blood samples that were obtain from severe COVID19 patients. It was also demonstrated that this antibody was able to effectively neutralize the virus. Parallel efforts are being made worldwide. Some have managed to isolate antibodies that neutralize other closely related viruses and even anti-SARS-CoV-2 monoclonal antibodies, but IIBR is the first to demonstrate that the antibody that was isolated from COVID19 patient can indeed neutralize this pathogen. IIBR will continue to characterize this antibody and others and a biological manufacture would be sought to mass produce it for clinical use.
IIBR researchers found that in heat conditions, characterized by the Israeli summer, the virus can survive on the surfaces for several hours compared to a few days at lower temperatures. In their opinion, there is no need for extensive disinfecting of the public spaces towards returning to the work routine.
The Israel institute for Biological research is considered to be one of the world's leaders in defense from chemical and biological threats. IIBR is the closest body in Israel to produce an effective vaccine for the corona virus, thanks to its scientist preparatory research
Hundreds of volatile chemical compounds are exhaled in breath. In order to find markers specific for Corona, they need to be detected, identified and mapped.
IIBR has developed unique methods for sensitive analysis and comprehensive data processing that are used in order to reliably identify these markers.
The Israel Institute for Biological Research and the Weizmann Institute of Science will join efforts in advancing research designed to develop ways to combat the coronavirus. A Memorandum of Understanding (MoU) between the two Institutes on this matter has been signed in recent days.
The researchers found that until Purim, the infection rate was too low to cause the mass spread of the virus. Their conclusions indicate that a few days of non-adherence are sufficient to lose control of the plague. An important lesson in preparation for the Passover holiday
"Significant progress" has been made in developing the vaccine and antibody for the novel coronavirus, according to a statement released by Israel's Prime Minister's Office on Tuesday.
IIBR Director General, Professor Shmuel Shapira, informed Prime Minister Benjamin Netanyahu of "significant progress" in designing a vaccine prototype and that the institute "is now preparing a model for commencing an animal trial".
IIBR will explore the potential of Dyadic's industrially proven C1 gene expression platform to express gene sequences and targets developed by IIBR into both an rVaccine candidate and monoclonal antibodies (mAbs) that may help combat the outbreak of the COVID-19 virus (Coronavirus).
Prof. Shmuel Shapira, Director General of The Israel Institute for Biological research, with a special article on synthetic biology as a new and powerful tool for life sciences, engineering and computing and IIBR role in the new revolution. “A research or biotechnological body that will not learn and utilize the potential of synthetic biology will soon become irrelevant".
A ten-week-old baby was hospitalized in intensive care following a rare poisoning that caused an obstruction in her nervous system. Unique cooperation between Soroka Hospital and the Israel Institute for Biological Research in Israel saved the infant's life
More than 50 experienced PhD scientists from the Israel institute for biological research, are working tirelessly to produce a vaccine and antibody for the Novel Coronavirus. This is a world-leading group in aspect of knowledge, experience and infrastructure.
The Israel institute for biological research is assigned by the Israeli Prime mister, Mr. Benjamin Netanyahu, to produce a vaccine and antibody for the Novel Coronavirus
At the 2019 CBI national
competition of “Beautiful and sustainable industry in a beautiful Israel” (January 9, 2020), the Israeli Institute for Biological Research was awarded with both a certificate of 5 beauty stars for quality of life and a sustainable environment and the Golden star for being awrded for the past five years
This year, out of admiration and solidarity with the population of Eshkol regional council, we have chosen to expand our "encounters with The Israel institute for Biological research's scientists" project and maintain a special scientific day in schools in Eshkol regional council.
During the day, more than 400 students from elementary and intermediate schools took part in numerous inspirational sessions in various fields of science
"Encounters with the Israel institute for Biological research's scientists" project, is on its sixth year. Every year, we deliver more than 45 experiential enrichment sessions for students in elementary and high schools in many cities and communities throughout Israel in hope to nurture and enrich scientific education.
The identification was based on a straightforward high-throughput sequencing (HTS) approach for the identification and characterization of unknown RNA viruses, after an initial electron microscopy imaging. This approach involved viral RNA extraction from the growth medium, rapid library preparation, HTS and bioinformatic viral identification, and was completed in less than 12 hours. In-depth genomic characterization utilizing various bioinformatics tools, further confirmed that the novel virus is indeed a new species, which was named "Ness Ziona virus". This work demonstrates the power of HTS, combined with bioinformatic tools, to rapidly identify and gain in-depth understanding of unknown and novel viruses in clinical samples.
The National Biological Laboratory of the Israel Institute for Biological Research identified the Monkeypox virus in a patient who returned from a visit to Nigeria.
Published in “Israel Hayom" 6.3.2019. From the article: “For years, I've known The Israel institute for biological research for its unique capabilities in developing and manufacturing vaccines. Unique capabilities that are in the forefront of knowledge and science in Israel and worldwide.As a doctor and an immunologist, I've been personally familiar with these capabilities that are also been published in scientific journals…"
New facility serves as a platform for conducting a variety of environmental experiments, without ever leaving the laboratory
Worldwide exclusive: A first-ever visit to the Israel Institute for Biological Research and an interview with its director, Col. (res.) Prof. Shmuel Shapira, who sheds some light on the secrets and operations of the mysterious institute.
Dyadic International, Inc. (“Dyadic”) (OTCQX:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development and production of biologic vaccines and drugs at flexible commercial scales, today announced that it has entered into a research and development collaboration with the Israel Institute for Biological Research (“IIBR”) to further advance its C1 expression platform for the development and manufacture of recombinant vaccines and neutralizing agents comprising targeted antigens and monoclonal antibodies, to combat emerging diseases and threats.